Skip to main content
. Author manuscript; available in PMC: 2019 Jul 30.
Published in final edited form as: Vaccine. 2018 Oct 14;36(48):7331–7337. doi: 10.1016/j.vaccine.2018.10.026

Table 4.

Comparison of averted cases determined by test methods 1–3*, by age group and season, 2010–11 to 2016–17.

Age Season Method 1 (currently used method)
Method 2
Method 3
Difference in averted cases compared with method 1, %
No. of averted cases Averted % No. of averted cases Averted % No. of averted cases Averted % Method 2 vs. Method 1 Method 3 vs. Method 1
All 2010–11 5,039,277 20.0 5,593,760 21.7 5,588,717 21.7 11.0 10.9
2011–12 1,981,571 18.2 2,179,701 19.7 2,179,404 19.7 10.0 10.0
2012–13 5,628,332 14.0 5,838,328 14.5 5,831,551 14.5 3.7 3.6
2013–14 6,683,929 19.5 7,199,195 20.6 7,192,944 20.6 7.7 7.6
2014–15 1,607,848 4.6 1,560,287 4.5 1,559,520 4.5 −3.0 −3.0
2015–16 5,083,498 17.2 5,645,614 18.8 5,642,695 18.8 11.1 11.0
2016–17 5,288,312 14.8 5,713,451 15.8 5,709,538 15.8 8.0 8.0
Median 17.2 18.8 18.8 8.0 8.0
6 m-4 y 2010–11 965,327 33.7 1,203,220 38.8 1,200,195 38.7 24.6 24.3
2011–12 241,406 27.7 282,620 30.9 282,496 30.9 17.1 17.0
2012–13 799,295 23.4 883,121 25.3 880,887 25.2 10.5 10.2
2013–14 741,609 30.6 875,027 34.2 873,252 34.2 18.0 17.8
2014–15 134,300 6.1 130,283 6.0 130,173 6.0 −3.0 −3.1
2015–16 980,052 32.3 1,212,842 37.1 1,211,129 37.1 23.8 23.6
2016–17 602,072 23.8 678,393 26.1 677,793 26.0 12.7 12.6
Median 27.7 30.9 30.9 17.1 17.0
5–17 y 2010–11 1,350,617 23.0 1,500,044 24.9 1,498,908 24.9 11.1 11.0
2011–12 490,865 20.0 540,115 21.6 540,075 21.6 10.0 10.0
2012–13 1,506,488 18.1 1,595,647 19.0 1,593,335 19.0 5.9 5.8
2013–14 1,081,574 21.9 1,179,996 23.4 1,179,153 23.4 9.1 9.0
2014–15 356,330 5.0 345,777 4.8 345,565 4.8 −3.0 −3.0
2015–16 1,281,134 24.3 1,454,669 26.7 1,454,025 26.7 13.5 13.5
2016–17 1,920,214 23.8 2,165,577 26.1 2,163,846 26.0 12.8 12.7
Median 21.9 23.4 23.4 10.0 10.0
18–49 y 2010–11 1,093,537 13.2 1,125,819 13.5 1,125,608 13.5 3.0 2.9
2011–12 445,893 11.5 462,906 11.9 462,877 11.9 3.8 3.8
2012–13 1,397,741 10.4 1,381,399 10.3 1,380,769 10.3 −1.2 −1.2
2013–14 2,174,882 14.8 2,220,864 15.0 2,219,686 15.0 2.1 2.1
2014–15 322,419 2.9 305,897 2.8 305,825 2.8 −5.1 −5.1
2015–16 1,591,114 14.1 1,671,719 14.7 1,671,462 14.7 5.1 5.0
2016–17 526,812 5.6 523,433 5.6 523,348 5.6 −0.6 −0.7
Median 11.5 11.9 11.9 2.1 2.1
50–64 y 2010–11 1,169,470 19.7 1,261,901 20.9 1,261,355 20.9 7.9 7.9
2011–12 488,982 20.5 537,764 22.1 537,698 22.1 10.0 10.0
2012–13 1,631,408 15.7 1,687,342 16.2 1,685,819 16.2 3.4 3.3
2013–14 2,213,864 21.6 2,400,974 23.0 2,398,707 23.0 8.5 8.3
2014–15 355,391 4.2 344,114 4.1 343,946 4.1 −3.2 −3.2
2015–16 743,725 9.6 765,353 9.9 765,189 9.9 2.9 2.9
2016–17 1,635,009 15.6 1,723,831 16.3 1,722,608 16.3 5.4 5.4
Median 15.7 16.3 16.3 5.4 5.4
≥65 y 2010–11 460,327 20.9 502,777 22.4 502,651 22.4 9.2 9.2
2011–12 314,425 24.5 356,296 26.9 356,258 26.9 13.3 13.3
2012–13 293,400 6.4 290,819 6.4 290,741 6.4 −0.9 −0.9
2013–14 472,000 23.6 522,334 25.5 522,146 25.5 10.7 10.6
2014–15 439,408 7.1 434,215 7.0 434,011 7.0 −1.2 −1.2
2015–16 487,473 22.4 541,031 24.3 540,890 24.3 11.0 11.0
2016–17 604,205 11.5 622,218 11.8 621,943 11.8 3.0 2.9
Median 20.9 22.4 22.4 9.2 9.2

Abbreviations: m, months; y, years.

*

Methods 1–3 are defined in Supplemental Tables 12 and the Methods section of text.